drugset / Trial / NCT04805333
Phase 1 Dose Escalation of ArtemiCoffee
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase I dose-escalation study of Artemisia annua (Aa) in patients with advanced ovarian cancer who have completed front-line chemotherapy with carboplatin and paclitaxel. The primary objective of this study is to determine the recommended phase II dose (RP2D) of Artemisia annua.
Timeline
- Start
- 2021-03-26
- Primary completion
- 2025-02-04
- Completion
- 2025-02-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Artemisia annua | Unknown | 450 mg | — |
| Subject | Artemisia annua | Unknown | 900 mg | — |
| Subject | Artemisia annua | Unknown | 1350 mg | — |
| Subject | Artemisia annua | Unknown | 1800 mg | — |